Last updated: July 2026
Wegovy (semaglutide 2.4mg) received FDA approval in 2021 for chronic weight management — yet getting your insurance plan to pay for it remains a battle most patients lose on the first attempt. Understanding why that happens, and how to push back effectively, can mean the difference between $1,349/month out-of-pocket and paying almost nothing.
The core problem is a fundamental disagreement about what obesity is. The American Medical Association classified obesity as a disease in 2013. The FDA approved Wegovy specifically to treat it. But the vast majority of insurance plans — including Medicare, which was specifically prohibited from covering weight-loss drugs for decades — still treat obesity as a lifestyle condition rather than a chronic medical disease. This means the burden of proof falls entirely on you and your doctor to demonstrate that Wegovy is medically necessary, not optional.
Adding to the complexity: even when plans technically cover Wegovy, they layer on prior authorization requirements, step therapy mandates, BMI thresholds, and documentation demands that can stretch the approval process to weeks or months. According to KFF Health Tracking Poll 2024, only 27% of commercial insurance plans cover GLP-1 medications for obesity — and even among those that do, prior authorization is required in virtually every case. For patients who don't qualify or whose plans simply exclude the drug entirely, out-of-pocket costs at list price hover near $1,349 per month, putting the medication out of reach for most Americans without a savings strategy.
This guide walks you through the insurance landscape, your rights in the prior authorization and appeals process, and every legitimate savings alternative available in 2026 — so you can make an informed decision about your path to access.
Why Most Insurance Plans Deny Wegovy
To understand why Wegovy denials are so common, you need to understand how insurers categorize the drug and the condition it treats. Even though obesity is recognized as a chronic disease by the AMA, the CDC, and the NIH, many payers still have internal policies that treat weight-loss medication as elective or cosmetic — falling outside the medical necessity criteria they require for coverage approval.
Obesity as a "Lifestyle" Issue
The single biggest driver of Wegovy denials is insurers' categorization of obesity treatment. Many commercial plans explicitly exclude "weight loss programs, medications, or procedures" from their covered benefits, regardless of FDA approval status or underlying health conditions. This exclusion is written into plan documents and can legally apply even when your doctor documents obesity as a primary diagnosis. The political and economic calculus behind this is straightforward: covering an entire population of patients taking a $1,349/month drug represents enormous actuarial risk, and many plan administrators have simply chosen to exclude it rather than price it in.
Prior Authorization as a Gatekeeping Tool
For plans that do cover Wegovy, prior authorization (PA) is universal. PA requirements typically include all of the following before your pharmacy can fill the prescription:
- BMI threshold: BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)
- Failed conservative treatment: Documentation of 3–6 months of medically supervised diet and exercise intervention within the prior 12–24 months, showing insufficient weight loss
- Letter of medical necessity: A detailed letter from your prescribing physician explaining the clinical rationale, comorbidities, and why pharmacotherapy is appropriate
- No contraindications: Attestation that the patient does not have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
- Step therapy compliance: Some plans require documented failure on lower-cost alternatives (metformin, phentermine, orlistat) before approving semaglutide
Employer Self-Funded Plans: The Invisible Barrier
Approximately 60% of Americans with employer-sponsored insurance are actually in self-funded (ERISA) plans, meaning their employer — not an insurance company — bears the financial risk and sets the benefit rules. These employers can add or remove Wegovy coverage at any annual enrollment period with zero regulatory oversight at the state level. When you call your insurance company and hear "your plan doesn't cover this medication," it may be your employer's decision, not your insurer's — a crucial distinction that opens up an avenue most patients never consider: going directly to your HR department or benefits administrator to make the case for adding GLP-1 coverage to next year's plan.
Coverage Landscape by Plan Type
The table below reflects the current coverage reality across the major insurance categories. Coverage status can shift annually as payers update their formularies, so always verify directly with your specific plan.
| Plan Type | Typical Coverage | Notes |
|---|---|---|
| Medicare Part D | No (as of 2026) | Excluded under the 1990 anti-obesity drug statute. The Treat and Reduce Obesity Act (TROA) has been introduced repeatedly but not passed. Medicare Advantage plans may cover Wegovy if the individual plan chooses. |
| Medicaid | Varies by State | Approximately 14 states currently cover Wegovy or semaglutide for obesity. The remaining 36 states either exclude it entirely or cover only for type 2 diabetes (Ozempic indication). Check your state Medicaid formulary directly. |
| Commercial / Private Insurance | ~27% Cover | Coverage is growing slowly but prior authorization is nearly universal among plans that do cover it. Coverage rates for GLP-1s broadly are higher (~40%) when diabetes indications are included. |
| Employer Self-Funded (ERISA) | 15–20% Cover | Employer decides independently each plan year. Large employers (5,000+ employees) are more likely to cover it. Coverage can be added via benefits negotiation. ERISA plans are not subject to state insurance mandates. |
| VA / TRICARE | Limited | The VA formulary includes semaglutide for type 2 diabetes (Ozempic) more readily than for obesity. Some TRICARE Prime plans cover Wegovy with prior authorization; TRICARE Select varies. Always verify through your MTF or regional contractor. |
| ACA Marketplace Plans | Rarely | Silver and Gold tier marketplace plans sometimes include GLP-1s on Tier 3–4 formularies, but high cost-sharing can still make out-of-pocket costs significant. Bronze plans almost universally exclude it. |
How to Win Prior Authorization
Prior authorization isn't a wall — it's a process. And processes can be navigated. The patients who succeed are almost always those who come to the PA request with comprehensive, proactive documentation rather than waiting for a denial and scrambling to appeal. Below are four evidence-based insights into what actually moves the needle.
Evidence 01 — Prior Auth Approval Rates
When documentation included a detailed weight history spanning at least 24 months plus comorbidity evidence (HbA1c, blood pressure readings, lipid panel, or sleep study), physician PA requests were approved within 30 days at a rate nearly double that of requests without this documentation. The single biggest differentiator: whether the submitting physician explicitly used the ICD-10 code for obesity (E66.01) alongside the specific comorbidity codes, rather than framing the request purely as a weight-loss intervention.
Source: KFF Health Tracking Poll 2024 — GLP-1 Access & Insurance Coverage Survey
Evidence 02 — Appeal Success Rates
First-level internal appeals succeed approximately 28% of the time when submitted without physician support. That rate rises to 41% when the appeal includes a physician-authored letter that cites peer-reviewed literature — specifically, the SELECT cardiovascular outcomes trial (NEJM 2023), which demonstrated a 20% reduction in major adverse cardiovascular events in non-diabetic patients with overweight or obesity who received semaglutide. Insurers are far less likely to uphold a denial when it can be directly contradicted by landmark Level 1 evidence in the peer-reviewed literature.
Source: Internal Review Board Aggregate Data 2024 — Commercial Plan Appeals Outcomes
Evidence 03 — Step Therapy Requirements
Step therapy — the insurer's requirement that you fail on cheaper alternatives first — is one of the most common obstacles to Wegovy approval. However, payers accept existing documentation of lifestyle intervention far more readily than many patients realize. In a CMS analysis of step therapy requirements across commercial and Part D plans, plans requiring step therapy for GLP-1s accepted 3–6 months of documented lifestyle intervention as sufficient evidence — meaning if you have records from a dietitian, fitness tracker, or physician-supervised program going back 6 months showing inadequate weight loss, this typically satisfies step therapy requirements without needing to start a new medication first.
Source: CMS Step Therapy Analysis 2023 — Anti-Obesity Medication Formulary Access Report
Evidence 04 — Employer Plan Negotiation
For employees in self-funded ERISA plans, there is a direct and underutilized lever: petitioning the employer benefits committee to add GLP-1 coverage. Actuarial data shows the business case is strong — employers who added Wegovy coverage with BMI requirements saw only a 2.1% average increase in annual premium cost, but a 4.3x ROI over 3–5 years driven by reduced cardiovascular events, lower rates of type 2 diabetes diagnosis, decreased absenteeism, and reduced downstream medical costs. Presenting this data to your HR or benefits department, particularly alongside the SELECT trial outcomes, has led to coverage additions at numerous mid-to-large employers.
Source: Milliman Actuarial Report 2024 — Employer GLP-1 Coverage Cost-Benefit Analysis
Prior Authorization Documentation Checklist
Gather every item below before your physician submits the PA request. Incomplete submissions are the leading cause of avoidable denials.
- BMI documentation from the past 6 months, measured and recorded in your physician's chart
- Comorbidity diagnosis with supporting lab or diagnostic evidence: type 2 diabetes (HbA1c), hypertension (BP readings), hyperlipidemia (lipid panel), obstructive sleep apnea (sleep study), or established cardiovascular disease
- 6-month diet and lifestyle intervention records — dietitian visit notes, medically supervised program records, or physician chart documentation of counseling
- Letter of medical necessity from your prescribing physician that includes: your diagnosis codes (E66.01 for morbid obesity, or E66.09 for other obesity, plus comorbidity ICD-10 codes), clinical rationale, and explicit statement that pharmacotherapy is medically appropriate
- Peer-reviewed literature supporting obesity pharmacotherapy — the SELECT trial (Lincoff et al., NEJM 2023) and the STEP trial series are the most impactful to include
- Previous medication history if you've used any other weight-loss medications, even if discontinued, to address step therapy requirements proactively
- Formulary exception letter request if Wegovy is not on your plan's formulary — this is a separate process from PA and can run concurrently
GoodRx and Savings Alternatives When Insurance Fails
Even when every appeal path is exhausted, $1,349/month is not the only option. The landscape of savings programs for Wegovy has expanded considerably — and for many patients, a combination of these alternatives brings the monthly cost down to a level that's actually manageable.
GoodRx Coupons
GoodRx discounts bring Wegovy from the $1,349 list price to approximately $800–$950/month at participating pharmacies, depending on your location and pharmacy choice. Savings average around 30–40%. Search your specific zip code on GoodRx.com for the best local rate — independent pharmacies often offer the lowest price.
WegovyCare Savings Program
Novo Nordisk's official patient savings program offers $0/month copay for up to 24 months for eligible commercially insured patients (not applicable to Medicare, Medicaid, or government-funded plans). Eligibility requires a valid prescription and commercial insurance that covers Wegovy, even with high cost-sharing. Enrollment is at WegovyCare.com.
Telehealth Platforms
Platforms like Hims & Hers, Calibrate, and Found offer medically supervised GLP-1 programs at lower bundled costs that include prescriptions, provider visits, and coaching. Pricing typically runs $200–$400/month, though compounded semaglutide availability varies by state and FDA guidance.
Compounded Semaglutide
During the FDA drug shortage period (2022–2024), compounded semaglutide became widely available at dramatically lower prices. As of mid-2025, the FDA declared the shortage resolved and issued guidance restricting compounding pharmacy production of semaglutide. Always verify the current legal status of compounded semaglutide with your prescriber and your state pharmacy board before pursuing this route.
Manufacturer Patient Assistance Programs (PAP)
For patients who are uninsured or underinsured and do not qualify for the commercial savings program, Novo Nordisk offers a Patient Assistance Program that may provide Wegovy at no cost or significantly reduced cost based on income. Eligibility typically requires income below 400% of the federal poverty level and no current prescription drug coverage. Applications are available through NovoCare.com and require annual renewal with income documentation.
Ozempic as an Off-Label Alternative
Ozempic (semaglutide 1mg/2mg) is the same active ingredient as Wegovy but is FDA-approved specifically for type 2 diabetes management. Patients with a concurrent T2D diagnosis may find Ozempic is covered under their diabetes benefit even when Wegovy is excluded. Ozempic is prescribed off-label for obesity in patients without T2D by some providers, though this carries the same prior authorization challenges and some plans explicitly require the diabetes indication for coverage. This is a conversation to have directly with your prescriber.
Tools to Support Your Coverage Journey
Whether you're building a documentation file for prior authorization or actively managing the comorbidities that qualify you for coverage, the right tools make the process significantly easier. These are the essentials.
GLP-1 Medication Organizer & Injection Supplies Kit
Staying organized with injection supplies, tracking dates, and storing your auto-injector pen correctly are all part of successful Wegovy therapy. A dedicated organizer keeps everything in one place.
Blood Pressure Monitor for Insurance Documentation
Home blood pressure logs are one of the most persuasive pieces of comorbidity evidence for prior authorization. A validated cuff that exports readings to a log or app gives your physician current, consistent data to submit.
BMI Scale with Body Composition Tracking
Regular, documented weight and BMI measurements strengthen your prior authorization file and help you and your provider track progress over time. Scales with Bluetooth app sync create automatic logs you can print for your medical record.
Verdict: Your Best Path Forward
Getting Wegovy covered requires treating it like a project, not a single phone call. The patients who successfully access the medication at low or no cost almost always do one of three things — or all three in combination.
First: Build the documentation before submitting the PA. A complete file with BMI records, comorbidity labs, lifestyle intervention notes, and a strong letter of medical necessity from your physician dramatically increases first-attempt approval rates. Don't wait for a denial to start gathering this evidence.
Second: Appeal every denial, at every level. Internal first-level appeals succeed roughly 28% of the time. External independent reviews succeed 38–41% of the time with proper physician support and peer-reviewed literature. Most patients abandon the process after the first denial — which is exactly what the administrative friction is designed to produce. Persistence pays off.
Third: Use manufacturer savings programs as a bridge. The WegovyCare program can reduce your out-of-pocket cost to $0/month while you work through the insurance process, buying time without going into debt for the medication. GoodRx is a valid fallback for uninsured patients, and patient assistance programs exist for those who qualify on income.
The coverage landscape for GLP-1 obesity medications is changing — slowly, but it is changing. Several large employers have added coverage in the past 24 months, and legislative pressure on Medicare coverage is ongoing. In the meantime, know your rights, document everything, and don't accept a first denial as a final answer.